Rich and diverse pipeline
Impactful solutions for AMR
BioVersys’ pipeline is focused on addressing the highest unmet medical needs in AMR. We focus on the WHO and CDC highest priority pathogens and the indications with no satisfactory treatment options to date. Our diverse portfolio of innovative, 1st in class and best in class assets is designed to improve patient outcomes.
Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
Partners
BV100 – novel MoA
Serious hospital infections -
A. baumannii
Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
BV100 – novel MoA
Serious hospital infections -
A. baumannii
Alpibectir – novel potentiator MoA
MDR-TB
TB Meningitis (TBM)
Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
Alpibectir – novel potentiator MoA
MDR-TB
TB Meningitis (TBM)
BV200 – novel anti-virulence MoA
S. aureus
Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
BV200 – novel anti-virulence MoA
S. aureus
BV500 - novel series
NTM infections
Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
BV500 - novel series
NTM infections
BV Discovery
Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
BV Discovery
Finding a diamond. BV100 has a novel mode of action addressing carbapenem resistant Acinetobacter baumannii (CRAB) lung and blood stream infections. CRAB is one of three highest priority pathogens on the WHO and CDC list and responsible for high mortality rates in intensive care units. BioVersys has developed and patented a new formulation of an already approved, safe drug that was previously unknown to be active on CRAB.
Creating a paradigm shift. Transcriptional Regulator Inhibitory Compounds (TRIC) have the potential to create a paradigm shift in treatment options for AMR and targeted microbiome manipulation. Alpibectir (BVL-GSK098) reverses the resistance and potentiates the activity of two anti-TB drugs, ethionamide (Eto) and prothionamide (Pto) used for the treatment of Tuberculosis.
BV200 abolishes toxin production of Staphylococcus aureus to address inflammation in atopic dermatitis patients and severe infections in hospitalised patients.